BioCentury's websites will be down for upgrades starting at 11 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Feb 08, 2010
 |  BC Week In Review  |  Clinical News  |  Regulatory

Silodyx/Urorec silodosin regulatory update

The EC approved an MAA from Recordati for Silodyx/Urorec silodosin to treat signs and symptoms of benign prostatic hyperplasia (BPH). Recordati plans to launch the selective adrenergic receptor alpha 1 (ADRA1)...

Read the full 141 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >